- Home
- BTMD vs STRO Comparison
BTMD vs STRO Comparison
Compare BTMD & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- STRO
- Stock Information
- Founded
- BTMD 2012
- STRO 2003
- Country
- BTMD United States
- STRO United States
- Employees
- BTMD N/A
- STRO N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTMD Health Care
- STRO Health Care
- Exchange
- BTMD Nasdaq
- STRO Nasdaq
- Market Cap
- BTMD 136.0M
- STRO 147.6M
- IPO Year
- BTMD N/A
- STRO 2018
- Fundamental
- Price
- BTMD $3.39
- STRO $0.74
- Analyst Decision
- BTMD Strong Buy
- STRO Buy
- Analyst Count
- BTMD 1
- STRO 7
- Target Price
- BTMD $8.00
- STRO $6.83
- AVG Volume (30 Days)
- BTMD 304.7K
- STRO 2.2M
- Earning Date
- BTMD 03-12-2025
- STRO 03-13-2025
- Dividend Yield
- BTMD N/A
- STRO N/A
- EPS Growth
- BTMD N/A
- STRO N/A
- EPS
- BTMD 0.09
- STRO N/A
- Revenue
- BTMD $197,191,000.00
- STRO $62,043,000.00
- Revenue This Year
- BTMD $17.51
- STRO N/A
- Revenue Next Year
- BTMD $15.84
- STRO N/A
- P/E Ratio
- BTMD $38.44
- STRO N/A
- Revenue Growth
- BTMD 6.38
- STRO N/A
- 52 Week Low
- BTMD $3.04
- STRO $0.72
- 52 Week High
- BTMD $8.44
- STRO $5.88
- Technical
- Relative Strength Index (RSI)
- BTMD 34.59
- STRO 26.77
- Support Level
- BTMD $3.04
- STRO $0.72
- Resistance Level
- BTMD $4.47
- STRO $0.80
- Average True Range (ATR)
- BTMD 0.33
- STRO 0.10
- MACD
- BTMD -0.01
- STRO -0.01
- Stochastic Oscillator
- BTMD 24.48
- STRO 5.68
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.